Analysis of Unusual Adverse Effects After Radium-223 Dichloride Administration
| Autor: | Viviana Frantellizzi, Mariano Pontico, Roberto Pani, Giuseppe De Vincentis, Arianna Pani |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pharmacology
medicine.medical_specialty business.industry Life quality Signs and symptoms Ra-223 dichloride lymphedema medicine.disease Article life quality 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Lymphedema 030220 oncology & carcinogenesis alpha particle therapy radiopharmaceutical adverse effects medicine Radiology Nuclear Medicine and imaging Radium-223 Dichloride Intensive care medicine business Adverse effect |
| Zdroj: | Current Radiopharmaceuticals |
| ISSN: | 1874-4710 |
| DOI: | 10.2174/1874471012666190927115331 |
| Popis: | Background: To our knowledge, no previous study or literature review has been performed about the effects of the extravasation of therapeutic radiopharmaceutical agents and its potential consequences, especially regarding alpha-particle emitting radiopharmaceuticals. Methods: Even if Radium-223 dichloride is known to be a relatively safe drug to manage, despite the correctness of the procedures applied , unexpected delayed adverse effects can occur. : In our vast experience, we rarely observed lymphedema, even after some time, at the site of administration. Results: Management of lymphedema caused by radiopharmaceuticals administration has been addressed through clinical examples. The sudden intervention allowed a fast remission of the signs and symptoms complained by patients treated with Radium-223 dichloride. Conclusions: The management of adverse effects after radiopharmaceuticals administration as in case of lymphedema onset, is extremely simple. These data confirm the safety of Radium-223 treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|